Is PT-141 (Bremelanotide) Legal in Tennessee?
Key numbers
- 1.75 mgVyleesi autoinjector strength, the only FDA-approved bremelanotide product, for premenopausal womenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 6 mmHgMaximal systolic blood pressure rise after each Vyleesi dose; diastolic rise is 3 mmHgSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40%Patients reporting nausea on Vyleesi, versus about 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- Federal status / Prescription drug, FDA-approved as Vyleesi, NDA 210557, approved June 21, 2019 [1][2]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Form and dose / 1.75 mg subcutaneous autoinjector, as needed, at least 45 minutes before anticipated sexual activity [1]
- Boxed warning and REMS / None in the prescribing information or the 2019 approval letter [1][2]
What federal law says
Bremelanotide is approved under NDA 210557 as Vyleesi, a 1.75 mg subcutaneous autoinjector, prescription only; the application was originally held by AMAG and is now held by Cosette Pharmaceuticals [1][2]. The approved use is premenopausal women with acquired, generalized HSDD: low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
Vyleesi has no boxed warning, and no REMS appears in the prescribing information or the 2019 approval letter [1][2]. The label contraindicates use in uncontrolled hypertension or known cardiovascular disease and says to assess cardiovascular risk and make sure blood pressure is well controlled before starting and periodically during treatment [1].
Questions worth asking
Is 'PT-141' the same product?
PT-141 was studied as an experimental peptide in animal research, and Vyleesi is the FDA-approved bremelanotide product [1][4]. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3].
Bremelanotide does not appear on FDA's page of bulk substances that may present significant safety risks or in any category on FDA's bulk-substance lists, and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [5][6][7].
What the label says to watch for
Each dose briefly raises blood pressure and lowers heart rate: maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute, usually back to baseline within 12 hours [1]. In an open-label study of 127 premenopausal women dosed once daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1].
Nausea was reported by 40% of patients versus about 1% on placebo; 13% needed anti-nausea medicine and 8% stopped the trials because of it [1]. Focal hyperpigmentation, including on the face, gums and breasts, was reported by 1% of patients receiving up to 8 doses a month versus none on placebo, and was more likely in patients with darker skin and with daily dosing [1]. Eighteen percent of patients on Vyleesi discontinued for adverse reactions versus 2% on placebo [1].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is PT-141 legal in Tennessee?
Does Vyleesi have a boxed warning or a REMS?
Does Vyleesi raise blood pressure?
Can men use bremelanotide?
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.
- Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-4.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Understanding Unapproved Use of Approved Drugs "Off Label" | FDA.